Mezzion Pharma
| Market cap | ₩2.2T |
| PE ratio | – |
| Forward PE | – |
| PB ratio | 55.49 |
| EPS | −₩903 |
| Dividend (yield) | – |
| Analysts (1–5) | – |
| Price target | – |
| Volume | 162,638 |
| Trading value | ₩11.0B |
| Day’s range | ₩64,300 – ₩70,900 |
| 52-week range | ₩45,850 – ₩179,900 |
| Foreign ownership KR | 22.73% |
| Foreign net buy (Oct 2) KR | −53,781 sh |
| Book value / share | ₩1,276 |
| Founded | 2002 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 2 | ₩68,000 | −53,781 | −1,226 | +52,709 | 22.73% |
| Oct 1 | ₩73,600 | −22,224 | +5,220 | +17,011 | 22.91% |
| Sep 30 | ₩72,900 | −21,870 | +13 | +21,803 | 23.06% |
| Sep 29 | ₩73,800 | −20,469 | −1,745 | +20,555 | 23.16% |
| Sep 28 | ₩78,800 | −73,544 | +216 | +73,328 | 23.17% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩31.7B | ₩8.6B | ₩7.9B | – |
| Operating income | −₩14.5B | −₩14.3B | −₩16.8B | – |
| Net income | −₩12.7B | −₩19.5B | −₩34.9B | – |
| Operating margin | −45.67% | −166.05% | −212.00% | – |
| Return on equity | −29.03% | −36.23% | −110.43% | – |
| Debt-to-equity | 49.97% | 60.65% | 470.09% | – |
| EPS | −₩451 | −₩653 | −₩1,160 | – |
| Dividend per share | – | – | – | – |
Peers
| Samyang Foods 003230 | ₩1,210,000 | −0.08% |
| Orion 271560 | ₩106,500 | +1.14% |
| CJ CheilJedang 097950 | ₩180,100 | +0.45% |
| Dong Suh Companies 026960 | ₩26,450 | −4.51% |
| Nongshim 004370 | ₩396,000 | −1.98% |
| Dongwon Industries 006040 | ₩35,300 | −0.14% |
About
Mezzion Pharma was founded in 2002 to make and sell pharmaceuticals, listed on the KOSDAQ in 2012, and focuses on new drug development for global markets. Its pipeline covers erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, single ventricle heart disease and autosomal dominant polycystic kidney disease. After filing a new drug application with the U.S. FDA for its single ventricle treatment, it is running an additional clinical trial.
Mezzion Pharma Co., Ltd. is listed on the KOSDAQ market of the Korea Exchange under the ticker 140410. Industry: Research & development.
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 6, 2026; investor flows as of Oct 2, 2026. Delayed data, not investment advice.